Bli medlem
Bli medlem

Du är här


PledPharma: Redeye: Pledpharma - Aladote upside

Redeye reiterates its base case valuation of SEK 15 following the Q1
2020 report. Due to the negative news about PledOx this year, our
valuation solely rests on Aladote, where we do see a credible pathway
forward, and we expect a pivotal Phase 2/3 trial can be initiated
about year-end.

Read more and download the Research Update:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.